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Background:  Aldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of 
the renin-angiotensin-aldosterone system. We investigated the renoprotective effect of the selective aldosterone receptor blocker 
eplerenone, the angiotensin converting enzyme inhibitor lisinopril, and combined eplerenone and lisinopril treatment in type 2 
diabetic rats. 
Methods:  Animals were divided into six groups as follows: Otsuka Long-Evans Tokushima Fatty (OLETF) rat control, OLETF 
rats treated with a low dose of eplerenone (50 mg/kg/day), OLETF rats treated with a high dose of eplerenone (200 mg/kg/day), 
OLETF rats treated with lisinopril (10 mg/kg/day), OLETF rats treated with a combination of both drugs (eplerenone 200 mg/kg/ 
day and lisinopril 10 mg/kg/day), and obese non-diabetic Long-Evans Tokushima Otsuka rats for 26 weeks. 
Results:  Urinary albumin excretion was significantly lower in the lisinopril group, but not in the eplerenone group. Urinary al-
bumin excretion was decreased in the combination group than in the lisinopril group. Glomerulosclerosis and renal expression 
of type I and type IV collagen, plasminogen activator inhibitor-1, transforming growth factor-β1, connective tissue growth fac-
tor, and fibronectin mRNA were markedly decreased in the lisinopril, eplerenone, and combination groups.
Conclusion:  Eplerenone and lisinopril combination showed additional benefits on type 2 diabetic nephropathy compared to 
monotherapy of each drug. 
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INTRODUCTION
Diabetic nephropathy is one of the common complications of 
diabetes, and often leads to end-stage renal insufficiency. The 
renin-angiotensin-aldosterone system (RAAS) has been known 
as a key mechanism of progressive renal injury in diabetic ne-
phropathy. Drugs blocking RAAS including angiotensin-con-
verting enzyme inhibitors (ACEI) or angiotensin II (Ang II) 
type 1 receptor blockers (ARB) have been exhibited to reduce 
proteinuria, tubulointerstitial fibrosis and glomeruolosclerosis 
[1,2]. However, neither ACEI nor ARB abrogate the progres-
sion of the diabetic nephropathy. This suggests that ACEI or 
ARB do not fully suppress aldosterone in some patients, so 
called ‘aldosterone escape phenomenon’ [3,4]. 
  Studies in experimental rat models have shown that aldoste-
rone participates to the progression of kidney disease through 
hemodynamic and direct cellular actions and antagonists of 
aldosterone retard the progression or cause regression of exist-
ing glomerulosclerosis independently of effects on blood pres-
sure [5-10]. Chrysostomou et al. [11] showed that spironolac-
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tone add-on therapy in diabetes patients who were taking ACEI 
had improvement in proteinuria. This suggests that more effi-
cient blocking of RAAS by combination of ACEI and aldoste-
rone receptor blocker may have additive renoprotective effects 
in diabetic nephropathy. However, the non-selective aldoste-
rone receptor blocker, spironolactone also works on progester-
one and androgen receptors to cause menstrual disorders in 
females, and gynecomastia in men. On the other hand, the se-
lective aldosterone receptor blocker, eplerenone selectively 
acts on the mineralocorticoid receptor to minimize these side 
effects [12].
  In the present study, we compared the effects of ACEI (lisin-
opril), eplerenone, and combination of lisinopril and eplere-
none on urinary albumin excretion, glomerulosclerosis and 
the expression of various pro-fibrotic cytokines in type 2 dia-
betic rat models.
METHODS
Animals
Fourteen-week-old Otsuka Long Evans Tokushima Fatty 
(OLETF) rats (type 2 diabetes animal model) and Long Evans 
Tokushima Fatty (LETO) rats (non-diabetic obese animal 
model) were supplied by the Tokushima Research Institute 
(Otsuka Pharmaceutical, Tokushima, Japan). Rats had free ac-
cess to rat chow and tap water, and were caged individually 
within a temperature and light-controlled environment. They 
were placed into the OLETF control group (OLETF); the OE 
50 group: 50 mg/kg eplerenone per day (Pfizer Inc., New York, 
NY, USA); and the OE 200 group: 200 mg/kg eplerenone per 
day; OA group: 10 mg/kg lisinopril per day (Hyundai Pharm., 
Seoul, Korea); OAE group: combined treatment of 10 mg/kg/
day lisinopril and 200 mg/kg/day eplerenone; and LETO group. 
The dosage of eplerenone and lisinopril was based on the re-
sults of a previous study [13,14]. Drug administration was 
continued until the rats were 40 weeks old, and body weight 
and blood pressure were measured at the end of the study pe-
riod. Blood pressure was measured by tail-cuff plethysmogra-
phy (LE 5001-Pressure Meter; Letica SA, Barcelona, Spain), 
and the mean value of 5 measurements were used. Rats were 
intraperitoneally injected with 50 mg/kg pentobarbital. After 
anesthesia, both kidneys were extracted, and one kidney was 
fixed in paraffin while the remaining kidney was frozen in liq-
uid nitrogen and preserved for the future analysis. All trials 
were conducted in accordance with the animal management 
guidelines of the Korea University College of Medicine.
Biochemical analysis
Urinary albumin concentration was measure by competitive 
ELISA kit (Shibayagi, Shibukawa, Japan), and urinary creati-
nine was determined by the modified Jaffe method. Urinary 
albumin excretion was quantified by a urinary albumin-to-
creatinine ratio and reported in micrograms of albumin per 
milligram of creatinine (μg/mg Cr). 
Glucose tolerance test
Forty-week-old rats were fasted for 10 hours and administered 
2.0 g/kg glucose intraperitoneally at 8:00 AM. Then, blood 
samples were taken from the tail vein and blood glucose was 
measured after 0, 30, 60, 90, and 120 minutes (Roche-Diag-
nostic, Pleasanton, CA, USA). 
Histological analysis
One kidney was stained with periodic acid-Schiff (PAS) im-
mediately after extraction, fixed in paraffin, and cut into 4 μm 
segments. An anti-quantitative score index [15] was used in 
order to evaluate the glomerulosclerosis score with PAS-stained 
tissue. Scores between 0 and 4 were given to glomeruli based 
on the assessment of degrees of sclerosis (no lesion: 0, sclerosis 
<25%: 1+, sclerosis 25% to 50%: 2+, sclerosis 50% to 75%: 3+, 
sclerosis >75%: 4+). One renal pathologist assessed over 50 
glomeruli from each rat in a blinded manner. The degree of 
sclerosis of each glomerulus was averaged and compared.
RNA extraction and analysis of gene expression
Total RNA was extracted from renal cortical tissue with 
TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), and fur-
ther purified using an RNeasy mini kit (Qiagen, Valencia, CA, 
USA). The nucleotide sequence of each primer was as follows:
  Transforming growth factor-β (TGF-β): sense 5ʹ-ATA-
CAGGGCTTTCGATCCAGG-3ʹ and anti-sense 5ʹ-GTCCAG-
GCTCCAAATATAGG-3ʹ; Type IV collagen: sense 5ʹ-TAG-
GTGTCAGCAATTAGGCAGG-3ʹ and anti-sense 5ʹ-CG-
GACCACTAT GCTTGAAGTGA- 3ʹ; Type I collagen: sense 
5ʹ-TCACCTACAGCACGCTTG-3ʹ and anti-sense 5ʹ- 
GGTCTGTTTCCAGGG TTG-3ʹ; Plasminogen activator in-
hibitor-1 (PAI-1): sense 5ʹ-ATGAGATCAGTACTGCGGAC-
GCCATCTTTG-3ʹ and anti-sense 5ʹ-GCACGGAGATGGT-
GCTACCATCAGACTTGT-3ʹ; Connective tissue growth fac-
tor (CTGF): sense 5ʹ-CTGAAAGAATAGCTGGCTTCA-3ʹ 130
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and anti-sense 5ʹ-CTGGTACTAGCTGAGGTCAT-3ʹ; Fibro-
nectin: sense 5ʹ-CTGGGATGCTCCTGCTGTCAC-3ʹ anti-
sense 5ʹ-CTGTTTGATCTGGACCTG CAG-3ʹ. 
  Using an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, 
USA), mRNA was reverse transcribed into cDNA, and the 
specificity of each polymerase chain reaction product was 
measured using a melting curve analysis. Then, a single band 
was confirmed through agarose gel electrophoresis. Real-time 
reverse transcription-polymerase chain reaction was performed 
by running for 10 minutes at 50°C, for 5 minutes at 95°C and 
denaturation for 10 seconds at 95°C, and then annealing and 
extension at 60°C for 30 seconds for 45 cycles. The results 
showed the β-actin expression level as a relative value. Gene 
expression was quantified using a Bio-Rad iCycler system 
(Bio-Rad).
Statistical analysis 
Results are presented as the value±standard deviation, and the 
natural log was taken for values which did not follow the nor-
mal distribution. One-way ANOVA and Duncan post-hoc 
analyses were used for comparison of more than two groups. 
Testing for statistical significance was performed using SPSS for 
windows version 17.0 (SPSS Inc., Chicago, IL, USA). Statisti-
cal significance levels with P values under 0.05 were consid-
ered significant.
RESULTS
Comparison of the clinical data at the end of the study
There was no significant difference in the weight between the 
drug-treated groups and the control group. The systolic blood 
pressure in the OA and OAE group was significantly lower than 
that of OLETF group. In contrast, there was no difference be-
tween the OE200 group and the OLETF group. High doses of 
eplerenone did not show a significant decrease in blood pres-
sure. Plasma creatinine levels are significantly increased in the 
OAE group. Fasting plasma glucose did not differ among the 
groups; however, 60 minutes plasma glucose after glucose load-
ing was significantly lower in the lisinopril treated groups (OA 
and OAE) than in the OLETF group. Plasma glucose after 120 
minutes of glucose loading was significantly lower in the OAE 
group compared to the OLETF group. Body weight, blood 
glucose, and urinary albumin excretion values were signifi-
cantly lower in the LETO group compared to the all OLETF 
groups (Table 1).
Twenty-four hour urinary albumin excretion 
Twenty-four hour urinary albumin excretion adjusted for uri-
nary creatinine was significantly lower in the OA and OAE 
groups than the OLETF group, and it was lowest in the OAE 
group, suggesting the additive effect of lisinopril and eplere-
none. Although eplerenone monotherapy groups (OE50, 
OE200) showed a decreasing trend of albuminuria compared 
to the OLETF group, it was not statistically significant. On the 
other hand, the OA group presented lower albuminuria than 
the OE200 group (Fig. 1).
Histological findings
Fig. 2A shows representative histologic findings in the experi-
mental groups. Diabetic OLETF rats showed more severe glo-
Table 1.  Clinical and laboratory data of experimental groups at the end of the study period 
OLETF OE50 OE200 OA OAE LETO
BW, g  640±22.3 612.5±25 587.5±70.3 591.6±58.5 570±67.1 516.6±28.9
SBP, mm Hg  147.2±18.4 134.7±9.78 152.3±9.93 119.3±13.6
 a,b 107.4±13.1
 a 128.5±20.6
sCr, mg/dL  0.58±0.13 0.58±0.05 0.63±0.052 0.58±0.075 0.76±0.055
 a,c 0.67 ±0.052
FPG, mg/dL 133.6±19.0 124.5±11.1 135.5±22.6 123.3±3.8 121.2±7.9 110.3±10.1
Glu60, mg/dL 323.4±93.9 231.25±11.1 250.5±97.8 186.8±27.2
 a 181.6±39.8
 a 181.83±13.3
 a
Glu120, mg/dL 223.2±64.5 159±30.8 233.3±84.5 165.2±21.6 116±24.9
 a,c 136.33±14.6
 a
Values are presented as the mean±standard deviation.
OLETF, Otsuka Long-Evans Tokushima Fatty (OLETF) rat control; OE50, OLETF rats treated with eplerenone at 50 mg/kg/day; OE200, 
OLETF rats treated with eplerenone at 200 mg/kg/day; OA, OLETF rats treated with lisinopril at 10 mg/kg/day; OAE, OLETF rats treated with 
lisinopril at 10 mg/kg/day and eplerenone at 200 mg/kg/day; LETO, non-diabetic control; BW, body weight; SBP, systolic blood pressure; sCr, 
serum creatinine; FPG, fasting plasma glucose; Glu60, plasma glucose after 60 minutes of oral glucose tolerance test; Glu120, plasma glucose 
after 120 minutes of oral glucose tolerance test.
aP<0.05 vs. OLETF, 
bP<0.05 vs. OE200, 
cP<0.05 vs. OA.131
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merulosclerosis than LETO rats. Eplerenone treatment signifi-
cantly reduced the degree of glomerulosclerosis and mesangial 
cell proliferation, compared to the untreated OLETF rats. Sim-
ilar findings were observed in the OA and OAE groups. The 
glomerulosclerosis index of the OE200, OA, and OAE groups 
were significantly lower compared to the OLETF control group 
(Fig. 2B). However, there was no statistically significant differ-
ence in the degree of glomerulosclerosis among the OE200, OA, 
and OAE groups. Although eplerenone and lisinopril both 
improved glomerulosclerosis, additional benefits could not be 
determined in the OAE group.
 
Expression of pro-fibrotic and pro-inflammatory cytokines
The expressions of type I and type IV collagen mRNA were 
lower in the OE50, OE200, OA, and OAE groups than in the 
OLETF group. Combination of lisinopril and eplerenone 
(OAE) group showed the decreased expression of type I and 
type IV collagen than lisinopril monotherapy (OA) group. The 
expressions of PAI-1, TGF-β, and CTGF mRNA in the OE50, 
OE100, OA, and OAE groups were lower than in the OLETF 
groups. However, their expressions were not different between 
the OA group and the OAE groups. Fibronectin mRNA ex-
pression was also lower in the OE50, OE200, and OA groups 
than in the OLETF groups (Fig. 3).
DISCUSSION
In this study, we investigated the effects of eplerenone and 
lisinopril monotherapy and their combination on diabetic ne-
phropathy in type 2 diabetic rat models. Even in low doses, 
eplerenone reduced the expression of type I collagen, type IV 
collagen, PAI-1, TGF-β, and fibronectin. High doses of eplere-
none improved glomerulosclerosis, and had a tendency to de-
crease albuminuria. Moreover, eplerenone and lisinopril com-
bination therapy lowered the expression of type I collagen and 
type IV collagen mRNA and albuminuria more than lisinopril 
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Fig. 1.  Effect of eplerenone and lisinopril on urinary albumin 
excretion. Twenty-four hour urinary albumin excretion was 
corrected by urine creatinine concentration. Values are present-
ed as mean±standard deviation. OLETF, Otsuka Long-Evans 
Tokushima Fatty (OLETF) rat control; OE50, OLETF rats treat-
ed with eplerenone at 50 mg/kg/day; OE200, OLETF rats treat-
ed with eplerenone at 200 mg/kg/day; OA, OLETF rats treated 
with lisinopril at 10 mg/kg/day; OAE, OLETF rats treated with 
lisinopril at 10 mg/kg/day and eplerenone at 200 mg/kg/day; 
LETO, non-diabetic control. 
aP<0.05 vs. OLETF, 
bP<0.05 vs. 
OE50, 
cP<0.05 vs. OE200, 
dP<0.05 vs. OA. 
OLETF OE50 OE200 OA OAE LETO
100
10
1
0.1
0.01
0.001
G
l
o
m
e
r
u
l
o
s
c
l
e
r
o
s
i
s
 
i
n
d
e
x
(
l
o
g
a
r
i
t
h
m
i
c
 
s
c
a
l
e
)
a a
a
a
Fig. 2.  Renal histologic findings and glomerulosclerosis index according to the treatment groups. (A) Renal histologic findings 
(periodic acid-Schiff [PAS] staining). (B) Glomerulosclerosis index according to the study groups on a logarithmic scale. PAS stain-
ing of glomeruli showed marked glomerulosclerosis in the OLETF group compared to treatment groups (×200). Glomeruloscle-
rosis indices are presented as mean±standard deviation. Statistical analysis was done after logarithmic transformation. OLETF, 
Otsuka Long-Evans Tokushima Fatty (OLETF) rat control; OE50, OLETF rats treated with eplerenone at 50 mg/kg/day; OE200, 
OLETF rats treated with eplerenone at 200 mg/kg/day; OA, OLETF rats treated with lisinopril at 10 mg/kg/day; OAE, OLETF 
rats treated with lisinopril at 10 mg/kg/day and eplerenone at 200 mg/kg/day; LETO, non-diabetic control. 
aP<0.05, vs. OLETF.
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monotherapy. The present study suggests that aldosterone re-
ceptor blocker and ACEI combination therapy in type 2 dia-
betic rat models prevents the progression of diabetic nephrop-
athy, which is consistent with several studies [8,15-19]. Re-
cently, Lee et al. [19] showed that spironolactone and losartan 
combination therapy reduced the expression of TGF-β, type 
IV collagen mRNA, and glomerulosclerosis in type 2 diabetic 
rat models. In addition, Kang et al. [20] also reported that 
eplerenone and enalapril combination therapy had additional 
effects on reducing urinary albumin excretion and glomerulo-
sclerosis.
  Aldosterone is known to stimulate the production of Ang II 
and independently cause toxicity and fibrosis of blood vessels 
through several mechanisms [4-7]. Aldosterone increases the 
production of fibronectin in mesangial cells through the 
Smad2-dependent TGF-β1 pathway [21], and promotes the 
expression of collagen genes through ERK1/2 in rat kidney fi-
broblasts [22]. In addition, aldosterone increases the expres-
sion of PAI-1 via serum- and glucocorticoid-inducible protein 
kinase 1 (SGK1), which is involved in signal transduction caus-
ing fibrosis of mesangial cells [23,24]. In the present study, low 
doses of eplerenone decreased the expression of these pro-fi-
brotic cytokines, and reduced glomerulosclerosis in the high 
doses. However, the reduction of albuminuria could not be 
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Fig. 3.  mRNA expression of pro-fibrotic and pro-inflammatory cytokines in renal cortical tissues in experimental animals. mRNA 
expression of (A) type I collagen, (B) type IV collagen, (C) plasminogen activator inhibitor-1 (PAI-1), (D) transforming growth 
factor-β (TGF-β), (E) connective tissue growth factor (CTGF), and (F) fibronectin are presented relatively compared to β-actin 
mRNA expression. Values are presented as mean±standard deviation. Statistical analysis was done after logarithmic transforma-
tion. OLETF, Otsuka Long-Evans Tokushima Fatty (OLETF) rat control; OE50, OLETF rats treated with eplerenone at 50 mg/kg/ 
day; OE200, OLETF rats treated with eplerenone at 200 mg/kg/day; OA, OLETF rats treated with lisinopril at 10 mg/kg/day; OAE, 
OLETF rats treated with lisinopril at 10 mg/kg/day and eplerenone at 200 mg/kg/day; LETO, non-diabetic control. 
aP<0.05, vs. 
OLETF, 
bP<0.05, vs. OA.133
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confirmed. It could be due to small sample size of rat model, 
or due to another unknown hemodynamic and metabolic fac-
tors affecting albuminuria. 
  In this study, lisinopril monotherapy had a more significant 
effect on blood pressure and albuminuria reduction compared 
to eplerenone. In addition, the blood glucose level 60 minutes 
after glucose loading in the lisinopril group was lower than in 
the eplerenone group, and after 120 minutes, the combination 
group showed a lower blood glucose value than the lisinopril 
monotherapy group. In the previous study, suppression of Ang 
II by ACEI and ARB promoted the differentiation of adipocytes 
and stimulated peroxisome proliferator-activated receptor-γ 
(PPAR-γ), improving insulin resistance [25,26]. In addition, 
when Miana et al. [27] used high doses of eplerenone, blood 
glucose levels were improved, which was reported to be asso-
ciated with PPAR-γ. In the Diabetes Reduction Assessment 
with Ramipril and Rosiglitazone Medication (DREAM) trials, 
although ramipril was ineffective in reducing the incidence of 
diabetes in patients with impaired glucose tolerance, the pro-
portion of subjects who regressed to the euglycemia was sig-
nificantly higher in the ramipril group [28]. This finding par-
tially demonstrated the hypoglycemic effects of ACEI; however, 
such effects of aldosterone inhibitors have not yet been identi-
fied in clinical studies.
  Eplerenone and lisinopril combination therapy was more 
effective in reducing urinary creatinine-adjusted 24-hour al-
bumin excretion than lisinopril monotherapy. When the simi-
larities in the blood pressure between the lisinopril monother-
apy group and the combination group were considered, an ad-
ditional effect of the combination therapy was independent 
from the hemodynamic effects of reduced blood pressure. There 
were no differences of the expression of pro-inflammatory and 
pro-fibrotic cytokines among combination group, high dose 
eplerenone group and lisinopril monotherapy group. Combi-
nation of ACEI and eplerenone may possess additional renal 
protective mechanism besides reducing the expression of these 
cytokines.
  However, a greater increase in plasma creatinine was ob-
served in the combination therapy group compared to the 
lisinopril monotherapy group. In the previous study to show 
the additive effect of enalapril and eplerenone on reducing al-
buminuria, although the creatinine clearance rate was initially 
decreased, it was recovered to the baseline level after 8 weeks 
of treatment [29]. Reduction of the glomerular filtration rate 
through the relaxation of the efferent arteriole during the ini-
tial period of ACEI therapy is well known [30], and the relax-
ation effect on renal arterioles from aldosterone antagonists is 
also known [31]. Thus, when eplerenone and lisinopril combi-
nation therapy is constantly used, renal perfusion is reduced, 
and plasma creatinine might increase. Unlike this study, Ma-
vrakanas et al. [32] showed that ramipril and eplerenone com-
bination therapy in streptozotocin-induced diabetic rats in-
creased creatinine clearance, and neither drug presented the 
improvement in mesangial hypertrophy. However, as their ex-
perimental period was 8 weeks after streptozotocin injection, 
it might be too short to demonstrate the beneficial effects of 
the treatment on histological changes. 
  In summary, eplerenone monotherapy exhibited the re-
duced expression of pro-inflammatory and pro-fibrotic cyto-
kines, although reduction of albuminuria was not evident. 
However, combination of lisinopril and eplerenone presented 
additive effect in reducting albuminuria compared to the 
monotherapy of each drug. Based on this investigation, in or-
der to minimize side effects and maximize the reno-protective 
effects of the combination therapy, prospective studies on the 
side effects and proper dosage of ACEI and aldosterone antag-
onist combination therapy are necessary. Furthermore, further 
studies to demonstrate the beneficial effects of this combina-
tion therapy on the late stage of diabetic nephropathy are also 
needed.
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